Home
| Log in or Sign Up for full access
| Tracked Organizations
| Recent Tracked Activities
Recent Activities
Activities between Nov. 15, 2024, 7:55 p.m. and Nov. 22, 2024, 7:55 p.m.
from: Diagnostics And Medical Devices.
Click on a document link to see the original source document.
Click on the name of an organization to see more organization linkages and timelines.
Document Date: Nov. 20, 2024, 11 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership:
Document Extract: Through this expanded partnership, Planet Innovation will support the development of Quantum-Si's Proteus instrument and serve as the contract manufacturing partner to ensure a seamless transition from development into commercialization. " We are thrilled to expand our partnership with Planet Innovation and leverage their global scale and expertise to accelerate the development and commercialization of Proteus ," said Jeff Hawkins, President and CEO of Quantum-Si. " We believe that partnering with Planet Innovation will allow us to deliver this novel instrument to the market on a timeline of under two years ." " Planet Innovation is proud to support Quantum-Si in developing their new proteomics platform. We have a large, established team with a proven track record in developing world-first life science platforms that are disruptive, compliant and commercialized in record time.
Document Source: https://www.businesswire.com/news/home/20241120378566/en/Quantum-Si-and-Planet-Innovation-to-Partner-on-Proteus%25E2%2584%25A2
(archive.org page /
archive.org listing)
Document Date: Nov. 20, 2024, 11 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership:
Document Extract: Quantum-Si and Planet Innovation to Partner on Proteus™. Quantum-Si Incorporated (Nasdaq: QSI) ("Quantum-Si ," "QSI" or the "Company") , The Protein Sequencing Company™, and Planet Innovation today announced that they will partner on the development and manufacturing of Quantum-Si's novel proteomics platform, Proteus™. Planet Innovation has a team of over four hundred people with expertise across design, development and manufacturing of scientific instrumentation and medical devices. Currently, Planet Innovation serves as the contract manufacturer for Quantum-Si's Platinum® Pro instrument, set to debut in the first half of 2025. Through this expanded partnership, Planet Innovation will support the development of Quantum-Si's Proteus instrument and serve as the contract manufacturing partner to ensure a seamless transition from development into commercialization.
Document Source: https://www.businesswire.com/news/home/20241120378566/en/Quantum-Si-and-Planet-Innovation-to-Partner-on-Proteus%25E2%2584%25A2
(archive.org page /
archive.org listing)
Document Date: Nov. 20, 2024, 11 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership:
Document Extract: Planet Innovation has a team of over four hundred people with expertise across design, development and manufacturing of scientific instrumentation and medical devices. Currently, Planet Innovation serves as the contract manufacturer for Quantum-Si's Platinum® Pro instrument, set to debut in the first half of 2025. Through this expanded partnership, Planet Innovation will support the development of Quantum-Si's Proteus instrument and serve as the contract manufacturing partner to ensure a seamless transition from development into commercialization. " We are thrilled to expand our partnership with Planet Innovation and leverage their global scale and expertise to accelerate the development and commercialization of Proteus ," said Jeff Hawkins, President and CEO of Quantum-Si. " We believe that partnering with Planet Innovation will allow us to deliver this novel instrument to the market on a timeline of under two years ."
Document Source: https://www.businesswire.com/news/home/20241120378566/en/Quantum-Si-and-Planet-Innovation-to-Partner-on-Proteus%25E2%2584%25A2
(archive.org page /
archive.org listing)
Document Date: Nov. 18, 2024, noon / Source: PR Newswire
Activity Class: PartnershipActivity
/ Region: Minneapolis
Partnership:
- ALZpath
/ Industry: Life Sciences And Technology
- Bio-Techne
/ Industry: Biotech And Technology, Diagnostics And Medical Devices and 4 more
- ALZpath
/ Industry: Life Sciences And Technology
- Bio-Techne Corporation
/ Industry: Biopharmaceutical And Biotech Industry, Biotech And Technology and 5 more
Document Extract: The ALZpath pTau217 (phosphorylated Tau217) antibody is the leading antibody used to detect the pTau217 biomarker. Increased levels of pTau217 are associated with amyloid plaques and tau tangles, the hallmark features of Alzheimer's disease. Running the Simple Plex Human Phospho Tau 217 ALZpath Assay on the Ella system will enable researchers to detect the pTau217 signal in less invasive sample collection types, like plasma samples, in just 90 minutes with no manual intervention, increasing efficiency, scalability, and precision while providing the necessary data to help accelerate clinical decisions. " Our partnership with ALZpath represents a major step forward in our commitment to advancing neurodegenerative disease research ," said Will Geist, President of Bio-Techne's Protein Sciences Segment. " We 're excited to see the impact that this easy-to-use, hands-free platform will have on advancing research in this critical field ."
Document Source: https://www.prnewswire.com/news-releases/bio-techne-and-alzpath-announce-strategic-partnership-to-advance-neurodegenerative-disease-research-302307463.html
(archive.org page /
archive.org listing)
Document Date: Nov. 21, 2024, 11 a.m. / Source: GlobeNewswire
Activity Class: PartnershipActivity
Partnership:
Document Extract: This collaboration aims to accelerate the development of advanced ceramic - based microspheres, a groundbreaking advancement in radiotherapeutic applications. The partnership will see SINTX leverage its expertise in ceramic manufacturing to support NED medical's pre-clinical testing needs and perform the necessary process validation and verification activities to transition the microsphere process from the R & D scale to pilot production. " Our successful manufacturing feasibility collaboration with NED Medical demonstrated that SINTX could manufacture novel ceramic - based microspheres containing the Yttrium-90 radioisotope that met NED Medical's preliminary specifications for a transarterial radioembolization (TARE) device for treatment of hepatocellular carcinoma. Further, these engineered microspheres contain porosity, allowing their future adaptation for targeted chemotherapy and combination therapies ," said Dr. Ryan Bock, CTO of SINTX Technologies. During this JDA, SINTX and NED Medical will collaborate closely, optimizing microsphere production, finalizing characterization and safety assessments, and producing microspheres needed to obtain pre-clinical data to be used as part of a device clearance submission.
Document Source: https://www.globenewswire.com/news-release/2024/11/21/2985021/30038/en/SINTX-Technologies-and-NED-Medical-Partner-to-Advance-Cutting-Edge-Ceramic-Microsphere-Medical-Devices-for-Cancer-Treatment.html
(archive.org page /
archive.org listing)
Document Date: Nov. 18, 2024, 6:30 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
/ Region: Republic of Panama
Partnership:
- Green Med Panama
/ Industry: Medical Devices And Equipment
- Ikonisys SA
/ Industry: Cancer Diagnostics, Hospital Management Service and 4 more
- Ikonisys SA
/ Industry: Cancer Diagnostics, Hospital Management Service and 4 more
Document Extract: Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the signing of a distribution agreement with Green Med, a major distributor of medical devices in Panama and Central America. This collaboration is part of a strategic initiative, which aims at bringing innovative cytological and oncological diagnostics to the region, based on four core initiatives. The first step of the plan focuses on certification and importation of Ikonisys Group's products into Panama, leveraging the region's logistical and operational advantages. Panama's strategic position as a logistics hub will enable streamlined distribution and access to Ikonisys Group's products across Central America (including Costa Rica, Nicaragua, Honduras, Salvador, Guatemala and Belize).
Document Source: https://www.businesswire.com/news/home/20241117538354/en/Ikonisys-Group-enters-Central-America-Market-through-a-Partnership-and-Distribution-Agreement-with-Green-Med-Panama
(archive.org page /
archive.org listing)
Document Date: Nov. 18, 2024, 6:30 a.m. / Source: Business Wire
Activity Class: PartnershipActivity
Partnership:
Document Extract: Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama. Regulatory News: Ikonisys SA (Euronext Growth Paris: ALIKO) , a company specializing in the early and accurate detection of cancers through a unique fully automated solution for medical analysis laboratories, today announces the signing of a distribution agreement with Green Med, a major distributor of medical devices in Panama and Central America. This collaboration is part of a strategic initiative, which aims at bringing innovative cytological and oncological diagnostics to the region, based on four core initiatives. The first step of the plan focuses on certification and importation of Ikonisys Group's products into Panama, leveraging the region's logistical and operational advantages.
Document Source: https://www.businesswire.com/news/home/20241117538354/en/Ikonisys-Group-enters-Central-America-Market-through-a-Partnership-and-Distribution-Agreement-with-Green-Med-Panama
(archive.org page /
archive.org listing)
Document Date: Nov. 20, 2024, 2:05 a.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity
/ Type: Ipo
/ Region: United States
Vendor:
Buyer:
- Carlyle Group
/ Industry: Accommodation Provider, Airline Services and 15 more
Document Extract: QuidelOrtho Corporation Announces Pricing of Secondary Offering of Common Stock by the Carlyle Group.
Document Source: https://www.businesswire.com/news/home/20241119268143/en/QuidelOrtho-Corporation-Announces-Pricing-of-Secondary-Offering-of-Common-Stock-by-the-Carlyle-Group
(archive.org page /
archive.org listing)
Document Date: Nov. 20, 2024, 2:05 a.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity
/ Type: Ipo
/ Region: United States
Vendor:
Buyer:
Document Extract: QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho") , a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the pricing of the previously announced underwritten secondary offering (the "Offering") by Carlyle Partners VI Cayman Holdings, L.P. (the "Selling Stockholder") of 8,260,183 shares of the Company's common stock ("Common Stock") .
Document Source: https://www.businesswire.com/news/home/20241119268143/en/QuidelOrtho-Corporation-Announces-Pricing-of-Secondary-Offering-of-Common-Stock-by-the-Carlyle-Group
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 9:54 p.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity
/ Type: Ipo
/ Region: United States
Vendor:
Buyer:
Document Extract: QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho") , a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today the launch of an underwritten secondary offering (the "Offering") by Carlyle Partners VI Cayman Holdings, L.P. (the "Selling Stockholder") of 8,260,183 shares of the Company's common stock ("Common Stock") .
Document Source: https://www.businesswire.com/news/home/20241112164377/en/QuidelOrtho-Corporation-Announces-Secondary-Offering-of-Common-Stock-by-the-Carlyle-Group
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 9:54 p.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity
/ Type: Ipo
/ Region: United States
Vendor:
Buyer:
- Carlyle Group
/ Industry: Accommodation Provider, Airline Services and 15 more
Document Extract: QuidelOrtho Corporation Announces Secondary Offering of Common Stock by the Carlyle Group.
Document Source: https://www.businesswire.com/news/home/20241112164377/en/QuidelOrtho-Corporation-Announces-Secondary-Offering-of-Common-Stock-by-the-Carlyle-Group
(archive.org page /
archive.org listing)
Document Date: Nov. 19, 2024, 12:34 a.m. / Source: GlobeNewswire
Activity Class: CorporateFinanceActivity
/ Type: Investment
/ Region: United States
Investor:
Target:
- Zenflow
/ Industry: Medical Devices And Equipment
Document Extract: Zenflow Announces $ 24 Million Financing Round to Fund FDA Filing & Commercial Preparation.
Document Source: https://www.globenewswire.com/news-release/2024/11/19/2983218/0/en/Zenflow-Announces-24-Million-Financing-Round-to-Fund-FDA-Filing-Commercial-Preparation.html
(archive.org page /
archive.org listing)
Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.
Treat sameAsNameOnly relationship as same? Yes
(Turn Off)
Site Stats
| About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License.
Please send an email if you need a non-share-alike license and/or you need API access.